1. Scrip
  2. >>Business

Denali Buyout Validates F-star’s Asset-Centric Model

 
• By Lucie Ellis-Taitt

Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.    

Roots
Denali claims CNS bispecific antibody partner F-star Gamma • Source: Shutterstock

Denali Therapeutics Inc. has exercised an option to acquire its partner F-star Gamma for $24m upfront, in a deal potentially worth more than $470m to the parent company F-star GMBH.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business